Company Overview and News
Investors will hope shares in mixer maker Fevertree Drinks will regain their fizz as it begins to step up its overseas expansion. The Aim-listed firm’s share price has surged 101pc in the last year but the market darling’s momentum was slowed in May when it failed to deliver its customary earnings upgrade. City analysts warned that investors may have to brace for a transition year as it tries to tap the huge US market to maintain its explosive growth.
KAZ RDS.B RDS.A AAL BATS RDSB 4162 RDSA JMPLF FQVTF FEVR AAUKF RYDBF JMPLY RYDAF NGLOY
KUALA LUMPUR (July 20): Maybank Investment Bank Bhd (Maybank IB) has reiterated a “hold” call on British American Tobacco (Malaysia) Bhd (BAT), as the company's 2018 second quarter results were within expectations.
KUALA LUMPUR, July 20 — Maybank Investment Bank Bhd (Maybank IB) has reiterated a “hold” call on British American Tobacco (Malaysia) Bhd (BAT), as the company’s 2018 second quarter results were within expectations.
BAT said it remained concerned with legal volumes continuing to be impacted by the current high incidence of illegal cigarette trade. The outlook for the second half of 2018, BAT said, would be very much dependant on the recovery of the legal market.
KUALA LUMPUR (July 19): Based on corporate announcements and news flow today, companies that may be in focus on Friday (July 20) may include the following: AirAsia, AirAsia X, APFT, BAT, CIMB, Malayan Flour Mills, PUC, Serba Dinamik and WZ Satu.
FLY 5238 7245 BATS 4162 SMHS 3662
KUALA LUMPUR (July 19): Owing to the market contraction, British American Tobacco (Malaysia) Bhd registered a 21.07% drop in net profit to RM113.72 million for the second quarter ended June 30.
KUALA LUMPUR (July 19): The FBM KLCI rose in early trade, lifted by select index-linked blue chips against the backfrop od mixed regional markets.
MLYBY MLYNF 4065 MS.PRE MS.PRF MS.PRG BATS 4162 MS.PRA 7153 5014 LIIHF 1155 MS.PRI MS.PRK MYPRY MS
Philip Morris International Inc. (PM - Free Report) is slated to release second-quarter 2018 results on Jul 19, before the opening bell. The company’s earnings have lagged estimates in three of the past four quarters, with an average miss of 1.5%. Well, this renowned tobacco company has been sailing on troubled waters, thanks to declining cigarette shipment volumes, triggered by government regulations to curb tobacco consumption and anti-tobacco campaigns.
HD PM VGR BATS 4162 MO
A mere two millennia after Roman politicians paid mobs to riot on their behalf, we are beginning to understand the role of dark money in politics, and its perennial threat to democracy. Dark money is cash whose source is not made public, and which is spent to change political outcomes. The Facebook/Cambridge Analytica scandal, unearthed by Carole Cadwalladr, and the mysterious funds channelled through Northern Ireland’s Democratic Unionist party to the leave campaign in England and Scotland have helped to bring the concept to public attention.
FB PM BATS 4162
Australia’s second richest person, Harry Triguboff, promised to create "one big happy family" at his $3 billion Pagewood Green residential development in Sydney’s eastern suburbs.
British American Tobacco (Malaysia) Bhd (July 16, RM33.10) Maintain add with a target price of RM38.66: Since the reformist Pakatan Harapan (Pakatan) coalition took over Malaysia’s federal government in May 2018, the optimism for British American Tobacco (BAT)’s earnings recovery has propelled the stock by 45.7% from its 11-year low of RM22.23. Even with the post-election jolt, BAT’s 1-year forward price earnings (P/E) of 15.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to LSE:BATS / BRITISH AMERICAN TOBACCO on message board site Silicon Investor.
|WIRX u003cthe old BATS u003e||BATS about Batteries Batteries, Inc.|